Answers are grounded in this paper and cite their sources.
Multiple myeloma (MM) is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies. With median age of 66 at the time of presentation, multiple myeloma is predominantly a disease of the elderly. The availability of new combination regimens and the enhanced safety of autologous hematopoietic stem cell transplant has increased the treatment options for elderly patients with multiple myeloma. We provide a summary of data supporting the current management of elderly patients with newly diagnosed multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Manapuram et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: